Navigation Links
Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report
Date:11/3/2008

ALBUQUERQUE, N.M., Nov. 3 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), a development stage medical diagnostics company, announced today that BUYINS.NET, http://www.buyins.net, is initiating coverage of Biomoda after releasing the latest short sale data to October 2008. From November 2006 to October 2008 approximately 13.6 million total aggregate shares of BMOD have traded for a total dollar value of nearly $3.6 million. The total aggregate number of shares shorted in this time period is approximately 1 million shares. The BMOD SqueezeTrigger price of $0.27 is the volume weighted average short price of all short selling in BMOD. The first of several short squeezes is expected to begin when shares of BMOD close above $0.05, where approximately 16,000 shares have been shorted. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

Month Total Vol. Short Vol. Avg. Price Short $ Value

November '06 1,350 104 $3.50 $364

December 12,500 963 $2.90 $2,791

January '07 476,123 36,661 $1.77 $64,982

February 306,044 23,565 $0.96 $22,682

March 381,010 29,338 $0.75 $22,077

April 442,725 34,090 $0.65 $21,988

May 1,092,498 84,122 $0.49 $41,430

June 1,750,488 134,788 $0.23 $31,001

July 2,658,260 204,686 $0.12 $23,539

August 1,565,381 120,534 $0.06 $7,774

September 423,743 32,628
'/>"/>

SOURCE Biomoda, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
2. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
3. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
4. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
5. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
6. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
7. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
8. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65
9. Vista Partners Updates Coverage; Maintains $3.20 Target Price
10. Neptune Technologies decided not to re-price options
11. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
Post Your Comments:
*Name:
*Comment:
*Email: